GynTect, a molecular diagnostic test developed by oncgnostics, allows reliable diagnostics of cervical cancer and the corresponding precancerous stages. The test has been revised now, offering an extension of its application, as compared to the first version. This extended version of GynTect is now available for use in laboratories. Moreover, oncgnostics has launched a crowd-investing campaign that offers small investors the opportunity to participate in the success of the company.

oncgnostics develops, based on proprietary epigenetic biomarkers molecular tests for reliable cancer diagnostics. This test allows reliable diagnostics of cervical cancer and its pre-stages. Now oncgnostics has raised a seven-digit Euro amount in a Series A financing round.